Skip to content. | Skip to navigation

Sections
Welcome to the APGI
The APGI is excited to see what new opportunities 'team science' collaboration will bring and remain committed to connecting Australian scientists, healthcare professionals and community members so that together we can improve outcomes for pancreatic cancer patients and their families.

Welcome to the APGI

The APGI is excited to see what new opportunities 'team science' collaboration will bring and remain committed to connecting Australian scientists, healthcare professionals and community members so that together we can improve outcomes for pancreatic cancer patients and their families.

The APGI brings together the expertise of pancreatic cancer scientists and healthcare professionals across Australia, and is dedicated to improving outcomes for pancreatic cancer patients and their families.

 

Established in 2009 with the aim to create a catalogue of genetic changes important in pancreatic cancer by using state of the art genome sequencing techniques.  This significant milestone was reached ahead of its goal in early 2014, with recruitment of our 750th APGI participant and submission of the 450th pancreatic cancer sample for genome sequencing.  This ambitious achievement has resulted in pancreatic cancer sequencing data being readily available to the research community from all over the world.

 

The APGI's ongoing mission is to further develop this existing world-class resource comprising biospecimens and comprehensive information on pancreatic cancer patients from diagnosis onwards, including clinical, genomic and outcome data and to use this resource to improve pancreatic cancer care in the era of personalised medicine.

 


 


IMPaCT Trial

Individualised Molecular Pancreatic Cancer Therapy (IMPaCT) is a new Australian clinical trial looking at individualising the treatment of patients with metastatic pancreatic cancer.

Get Email Updates
Familial Cancer Cohort

Do you have a family history of pancreatic cancer? We need your help. You may also be eligible to join our screening program. Click here to find out more.

Make a Donation

Ensure our work continues, make a donation

APGI News
APGI 2016 Symposium - Register Now

The Australian Pancreatic Cancer Genome Initiative (APGI) 6th Annual Clinical & Scientific Symposium is on in Sydney - Saturday 18th June, 2016. International and national speakers include Professor Andrew Biankin & Professor Sean Grimmond.

Ground breaking research - but what does this mean for pancreatic cancer patients?

Published earlier this month, a study led by APGI researchers has provided the most in-depth analysis yet of pancreatic cancer, re-classifying this disease into four subtypes, each with its own genetic make-up and distinct behaviour. This gives us insight into why tumours seem to act differently in individual patients.

Comprehensive analysis of the blueprint of pancreatic cancer.

APGI lead study published in Nature today reveals that pancreatic cancer is at least four separate diseases each with a different cause and needing a different treatment.

International Symposium on Pancreatic Cancer 2016

The International Symposium on Pancreatic Cancer 2016 will be hosted by our colleagues at the Wolfson Wohl Cancer Research Centre and held at the University of Glasgow, Scotland 9th - 12th June 2016. This conference will bring together 350 medical oncologists, surgeons, radiographers, gastroenterologists, molecular pathologists, pathologists and clinical and basic scientists from all over the globe, to explore current knowledge in the diagnosis and treatment of pancreatic cancer.

APGI Proud Recipient of Avner Foundation Accelerator Grant

In its 2015 inaugural funding round The Avner Pancreatic Cancer Foundation has made available $1.9M in grant funding to support research into pancreatic cancer. This funding pool was raised through incredible corporate and community fundraising efforts across the country and has translated into a total of six Grants.